66 related articles for article (PubMed ID: 10627634)
1. Increased Serum Levels of N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) in Mobilized Healthy Donors with G-CSF: A Cohort Study.
Cid J; Guinetti-Ortiz K; Charry P; Carbassé G; de Pablo-Miró M; Rubia L; Garcia M; Alcaraz-Quiles J; Cascos E; Martínez-Cibrian N; Salas MQ; Suárez-Lledó M; Rosiñol L; Fernández-Avilés F; Martínez C; Rovira M; Lozano M
Transfus Med Rev; 2024 Apr; 38(2):150824. PubMed ID: 38569349
[TBL] [Abstract][Full Text] [Related]
2. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial.
Karpova D; Bräuninger S; Wiercinska E; Krämer A; Stock B; Graff J; Martin H; Wach A; Escot C; Douglas G; Romagnoli B; Chevalier E; Dembowski K; Hooftman L; Bonig H
J Transl Med; 2017 Jan; 15(1):2. PubMed ID: 28049490
[TBL] [Abstract][Full Text] [Related]
3. Psychological and physical side effects during G-CSF mobilization in related donors of allo-HCT.
Cai L; Jin D; Lai J; Li L; Luo Y; Shi J; Lai X; Liu L; Zhao Y; Yu J; Qiu Y; Song K; Yu F; Guo Q; Jin A; Huang H; Ding S; Ye Y
Ann Hematol; 2024 Apr; ():. PubMed ID: 38637333
[TBL] [Abstract][Full Text] [Related]
4. Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF.
Stroncek DF; Dittmar K; Shawker T; Heatherman A; Leitman SF
J Transl Med; 2004 Jul; 2(1):25. PubMed ID: 15268759
[TBL] [Abstract][Full Text] [Related]
5. Pain is what hurts: An exploration of perception and management of pain in peripheral blood stem cell donors.
van Walraven SM; Witte LC; Prinsze F; Wiersum-Osselton JC; Bank I
Transfus Apher Sci; 2024 Jun; 63(3):103908. PubMed ID: 38519381
[TBL] [Abstract][Full Text] [Related]
6. Polymer conjugation of proteins as a synthetic post-translational modification to impact their stability and activity.
Wright TA; Page RC; Konkolewicz D
Polym Chem; 2019 Jan; 10(4):434-454. PubMed ID: 31249635
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors.
Newell LF; Shoop KM; Knight RJ; Murray SN; Kwock RP; Jacoby CE; Slater S; Allen BE; Ottowa C; Cota B; Appel PL; Cook RJ; Maziarz RT; Meyers G
Cytotherapy; 2019 Jul; 21(7):725-737. PubMed ID: 31085121
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
Wallis WD; Qazilbash MH
World J Transplant; 2017 Oct; 7(5):250-259. PubMed ID: 29104859
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Stem Cells Mobilization Strategies to Ameliorate Patient Outcomes: A Review of Guide- lines and Recommendations.
Mohammadi S; Malek Mohammadi A; Nikbakht M; Norooznezhad AH; Alimoghaddam K; Ghavamzadeh A
Int J Hematol Oncol Stem Cell Res; 2017 Jan; 11(1):78-88. PubMed ID: 28286619
[TBL] [Abstract][Full Text] [Related]
10. Cytokine therapy-mediated neuroprotection in a Friedreich's ataxia mouse model.
Kemp KC; Cerminara N; Hares K; Redondo J; Cook AJ; Haynes HR; Burton BR; Pook M; Apps R; Scolding NJ; Wilkins A
Ann Neurol; 2017 Feb; 81(2):212-226. PubMed ID: 28009062
[TBL] [Abstract][Full Text] [Related]
11. An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.
Shin KH; Lim KS; Lee H; Jang IJ; Yu KS
Invest New Drugs; 2014 Aug; 32(4):636-43. PubMed ID: 24468886
[TBL] [Abstract][Full Text] [Related]
12. Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.
Lundqvist A; Smith AL; Takahashi Y; Wong S; Bahceci E; Cook L; Ramos C; Tawab A; McCoy JP; Read EJ; Khuu HM; Bolan CD; Joo J; Geller N; Leitman SF; Calandra G; Dunbar C; Kurlander R; Childs RW
J Immunol; 2013 Dec; 191(12):6241-9. PubMed ID: 24244025
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.
Waller CF; Bronchud M; Mair S; Challand R
Ann Hematol; 2010 Oct; 89(10):971-8. PubMed ID: 20567823
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.
Waller CF; Bronchud M; Mair S; Challand R
Ann Hematol; 2010 Sep; 89(9):927-33. PubMed ID: 20428872
[TBL] [Abstract][Full Text] [Related]
15. Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia.
Müller LU; Williams DA
Mutat Res; 2009 Jul; 668(1-2):141-9. PubMed ID: 19508850
[TBL] [Abstract][Full Text] [Related]
16. Stem cell bioprocessing: fundamentals and principles.
Placzek MR; Chung IM; Macedo HM; Ismail S; Mortera Blanco T; Lim M; Cha JM; Fauzi I; Kang Y; Yeo DC; Ma CY; Polak JM; Panoskaltsis N; Mantalaris A
J R Soc Interface; 2009 Mar; 6(32):209-32. PubMed ID: 19033137
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic peripheral blood stem cell collection as of 2008.
Rhodes B; Anderlini P
Transfus Apher Sci; 2008 Jun; 38(3):219-27. PubMed ID: 18501676
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors.
Martínez C; Urbano-Ispizua A; Marín P; Merino A; Rovira M; Carreras E; Montserrat E
Bone Marrow Transplant; 1999 Dec; 24(12):1273-8. PubMed ID: 10627634
[TBL] [Abstract][Full Text] [Related]
19. [Collection of hematopoietic progenitor cells from healthy donors].
Bojanić I; Cepulić BG; Mazić S
Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
